SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Sanofi CEO Belén Garijo
C-suite
Garijo starts as Sanofi CEO with window to ease reliance on Dupixent
The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on its cornerstone immunology product.
April 28, 2026
 · 
4 min read
 · 
Nick Paul Taylor
3d rendering of a red and silver realistic model of a retro rocket stands crashed into a wooden desk on a blue background. Failed launch. Technological progress. Technical mistake.
Liver cancer
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
April 27, 2026
 · 
2 min read
 · 
Annalee Armstrong
Abstract Weather Concept - Sun In Serene Sky With Flare Effect
Deals
Sun Pharma beams up Organon in $11.75B acquisition
Sun Pharmaceutical is bringing Merck spinoff Organon into the fold, paying $11.75 billion in hopes of becoming a top global biosimilar player.
April 27, 2026
 · 
1 min read
 · 
Gabrielle Masson
Big fish with dollar sign eating many small ones. Competition, merger, business, monopoly concept. EPS 8 vector illustration, no transparency
Deals
Lilly lands third oncology deal in 3 weeks, inking up to $2.3B for Ajax
Eli Lilly is picking up Ajax Therapeutics and its once-daily oral blood cancer candidate. The deal follows the pharma’s buyouts of ADC specialist CrossBridge Bio and in vivo CAR T company Kelonia Therapeutics.
April 27, 2026
 · 
2 min read
 · 
Gabrielle Masson
Inspiration Business Opportunity. Businessman looks at stairs in the door arrow pointing up
Gene editing
Intellia heads to FDA after notching first late-stage win for in vivo gene editor
With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for hereditary angioedema.
April 27, 2026
 · 
3 min read
 · 
Tristan Manalac
scientists couple holding barrels with warning sign african american man woman in protective suits working with chemicals research science concept modern laboratory interior full length horizontal vector illustration..
Manufacturing
UCSF, Par Health hit with FDA warning letters for environmental monitoring issues
FDA inspectors warned UCSF radiopharmaceutical facility that losing environmental control could pose a serious hazard to patients.
April 27, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Perspective way to invest money. Hands with dollar sign coins around yellow light bulb over blue background
Funding
Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases
George Church’s Rejuvenate Bio is turning to social networks to help fund its work on one-time gene therapies targeting chronic diseases and root causes of aging.
April 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Inclusion of new taxes into the price and increase in cost. Include inflation and costs for pricing. Increase in cost of electricity, fuel, increase in wages for workers or theft in the store.
Drug pricing
J&J puts blockbuster blood thinner Xarelto on TrumpRx
After striking a Most Favored Nation deal with the White House in January, Johnson & Johnson will now offer Xarelto at 68% off on TrumpRx, dropping its price from $611.82 to $197 per 30-pill pack.
April 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Sponsored
Turn health data into impact: Browns University’s online master in biostatistics & health data science
Trained biostatisticians play a central role in clinical science and public health. Brown’s online master’s in biostatistics (health data science concentration), prepares you with a strong foundation in biostatistical and data science methods combined with rigorous training in applied skills to make critical data-driven decisions and meet the growing demand for leaders in this industry – on your schedule
April 27, 2026
 · 
3 min read
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS